RAA, a Selective Retinoic Acid Receptor Alpha Agonist as a predictor of response to SY-1425 in patients with Acute Myeloid Leukemia (AML) compared to Myelodysplastic Syndrome (MDS)

Trial Profile

RAA, a Selective Retinoic Acid Receptor Alpha Agonist as a predictor of response to SY-1425 in patients with Acute Myeloid Leukemia (AML) compared to Myelodysplastic Syndrome (MDS)

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Tamibarotene (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top